BACKGROUND: The management of trigeminal neuralgia in patients with associated skull base meningiomas is complex. OBJECTIVE: We evaluated the pain management needs and outcomes in patients with petroclival meningiomas associated with medically refractory trigeminal neuralgia. METHODS: During a 21-year period, 168 patients underwent stereotactic radiosurgery (SRS) for meningiomas involving the petroclival region. We identified 12 patients (10 females; median age 54 years) who had trigeminal neuralgia in association with an ipsilateral petroclival meningioma. The median tumor volume was 3.8 cm(3) (1.0-15.9 cm(3)). The median prescription dose for tumor margins was 13 Gy (11-16 Gy). RESULTS: Initial pain control [Barrow Neurological Institute (BNI) grades I-IIIb] was obtained in 10 of 12 patients (83%). However, 3 patients with initial adequate relief later developed pain. Follow-up imaging revealed control of tumor growth in all patients at a median follow-up of 68 months. No patient developed any new sensory dysfunction. The tumor shrinkage was not associated with pain relief. At the final follow-up, 5 patients had pain of BNI grade I (2 after surgery), 4 had grade IIIb and 3 had grade IV. CONCLUSIONS: SRS provided effective tumor control, but trigeminal neuralgia persisted to varying degrees in most patients. Multimodality pain management strategies were required in most patients with skull base meningiomas associated with trigeminal neuralgia.
BACKGROUND: The management of trigeminal neuralgia in patients with associated skull base meningiomas is complex. OBJECTIVE: We evaluated the pain management needs and outcomes in patients with petroclival meningiomas associated with medically refractory trigeminal neuralgia. METHODS: During a 21-year period, 168 patients underwent stereotactic radiosurgery (SRS) for meningiomas involving the petroclival region. We identified 12 patients (10 females; median age 54 years) who had trigeminal neuralgia in association with an ipsilateral petroclival meningioma. The median tumor volume was 3.8 cm(3) (1.0-15.9 cm(3)). The median prescription dose for tumor margins was 13 Gy (11-16 Gy). RESULTS: Initial pain control [Barrow Neurological Institute (BNI) grades I-IIIb] was obtained in 10 of 12 patients (83%). However, 3 patients with initial adequate relief later developed pain. Follow-up imaging revealed control of tumor growth in all patients at a median follow-up of 68 months. No patient developed any new sensory dysfunction. The tumor shrinkage was not associated with pain relief. At the final follow-up, 5 patients had pain of BNI grade I (2 after surgery), 4 had grade IIIb and 3 had grade IV. CONCLUSIONS:SRS provided effective tumor control, but trigeminal neuralgia persisted to varying degrees in most patients. Multimodality pain management strategies were required in most patients with skull base meningiomas associated with trigeminal neuralgia.
Authors: Robert Starke; Hideyuki Kano; Dale Ding; Peter Nakaji; Gene H Barnett; David Mathieu; Veronica Chiang; James B Yu; Judith Hess; Heyoung L McBride; Norissa Honea; John Y K Lee; Gazanfar Rahmathulla; Wendi A Evanoff; Michelle Alonso-Basanta; L Dade Lunsford; Jason P Sheehan Journal: J Neurooncol Date: 2014-05-13 Impact factor: 4.130
Authors: Andrew Faramand; Hideyuki Kano; Ajay Niranjan; Stephen A Johnson; Mohab Hassib; Kyung-Jae Park; Yoshio Arai; John C Flickinger; L Dade Lunsford Journal: J Neurooncol Date: 2018-04-24 Impact factor: 4.130